Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial

In patients with severe portal hypertension (all with high-risk varices) and suboptimal hemodynamic response to traditional NSBBs, combined therapy with carvedilol plus simvastatin significantly enhances the portal pressure reduction achieved with carvedilol monotherapy, improves endothelial dysfunction, and reduces proinflammatory cytokines.

Authors

Institutions

Publication Details

Journal
Hepatology
Published
2024-11-07
DOI
https://doi.org/10.1097/hep.0000000000001148
Citations
13
Primary Topic
Liver Disease and Transplantation
Type
article
Field-Weighted Citation Impact
4.80
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial

Anna Brujats, Ángela Puente, Rosa Montañés, Edilmar Alvarado‐Tápias et al.
13 citations
Hepatology
Liver Disease and Transplantation
4.80
article

Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial

Anna Brujats, Ángela Puente, Rosa Montañés, Edilmar Alvarado‐Tápias, Xavier Torras, Álvaro García‐Osuna, Elisabet Cantó, Oana Pavel, Carles Aracil, Àngels Escorsell, Alba Ardèvol, Ainhoa Rodríguez‐Arias, Javier Antonio Tamayo Fajardo, Berta Cuyàs, Marta Garcia‐Guix, Càndid Villanueva, María Poca
article en
13 citations

Abstract

In patients with severe portal hypertension (all with high-risk varices) and suboptimal hemodynamic response to traditional NSBBs, combined therapy with carvedilol plus simvastatin significantly enhances the portal pressure reduction achieved with carvedilol monotherapy, improves endothelial dysfunction, and reduces proinflammatory cytokines.

HepatologyVol. 82(1)
Universitat Autònoma de Barcelona (ES), Instituto de Salud Carlos III (ES), Hospital de Sant Pau (ES), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES), Institut de Recerca Sant Pau (ES)
Good health and well-being
Openalex Percentile: Top 4%
Liver Disease and Transplantation
4.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.